MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Potential BlockBuster Technology and/or Business Model
Pioneers: Triple Helix: New Business Models_Open Innovation, Virtual Organizations, Royalty Aggregators, Etc.
RICS (Regional Innovation Clusters) - Medical, Life Sciences & Emerging Technology Hotspots
*Industry: New York City
Royalty Pharma plc (NASDAQ:RPRX)
Finance & Acquisitions: Royalty Pharma
PTC Therapeutics, Inc (NASDAQ: PTCT)*
Organization & Developments: PTC Therapeutics
Parents
PTC Therapeutics, Inc (NASDAQ: PTCT)*
Children
*PTCs compounds modulate gene expression by selectively binding to either RNA targets or to proteins that interact with RNA.
*RNA biology and chemistry platforms
2011: PTC Therapeutics has agreed to a licensing deal with Swiss pharmaceutical firm Roche for its spinal muscular atrophy program
2017: PTC Therapeutics' Long Road To Nowhere_seekingalpha
2018: PTC Therapeutics Surges On Positive Outcome From Rare Disease Study_seekingalpha.com
2018: PTC Therapeutics' RG7916 shows positive effect in mid-stage SMA-1 study; shares ahead 8% premarket - PTC Therapeutics (NASDAQ:PTCT)
2019: PTC Therapeutics: Opportunity After Secondary Offering?_seekingalpha.com
2020: PTC Therapeutics taps experimental cancer drug for new COVID-19 trial
2022: PTC Therapeutics: PKU Trial News Likely To Shore Up Share Price_ seekingalpha.com
2024: Novartis pays PTC $1B upfront for midphase Huntington's program, reestablishing itself in R&D race
2024: PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program
2024: PTC Therapeutics: ALS Drug Fail Kicks Off Critical Year Of Catalysts
2025: PTC Therapeutics: HD Treatment Advancement Continues With Q4 2025 Catalyst
2025: PTC Therapeutics: Upside In Rare Disease Innovation_seekingalpha.com
Jumps
*Key People: PTC Therapeutics
Finance & Acquisitions: PTC Therapeutics